Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.56 CAD | +1.30% | +4.70% | -12.85% |
Apr. 11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
Apr. 11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.85% | 84.41M | |
+19.63% | 42.68B | |
-3.04% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.31% | 24.94B | |
-20.24% | 18.96B | |
+30.21% | 12.3B | |
-2.69% | 11.95B | |
-2.73% | 11.55B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA